Skip to main content

Advertisement

SpringerLink
Log in

Detection of ESR1 mutations in plasma and tumors from metastatic breast cancer patients using next-generation sequencing

  • Preclinical study
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Purpose

Liquid biopsy using digital PCR (dPCR) has been widely used for the screening of ESR1 mutations, since they are frequently identified in the hotspot. However, dPCR is limited to the known mutations. Therefore, we aimed to analyze the utility of next-generation sequencing (NGS) to discover novel ESR1 mutations.

Methods

Whole exon sequencing of the ESR1 gene using NGS was performed in 16 primary and 47 recurrent tumor samples and 38 plasma samples from hormone receptor-positive metastatic breast cancer patients. Functional analyses were then performed for the novel mutations we detected.

Results

We identified no mutations in primary tumors and six mutations in five recurrent tumors, including three types of known mutations (Y537C, Y537N, and D538G) and two novel mutations (E279V and G557R). We also identified seven mutations in five plasma samples, including three types of known mutations (S463P, Y537S, and D538G) and one mutation not reported in COSMIC database (L536H). All nine patients with ESR1 mutations were treated with aromatase inhibitors (AIs) prior to sampling, and the mutations were frequently detected in patients who received AI treatments in the metastatic setting. Among the three novel mutations (E279V, L536H, and G557R), L536H, but not E279V and G557R, showed ligand-independent activity. All three mutant proteins showed nuclear localization and had no relation with non-genomic ER pathways.

Conclusions

Although the molecular mechanisms of the E279V and G557R mutations remain unclear, our data suggest the utility of NGS as a liquid biopsy for metastatic breast cancer patients and the potential to identify novel ESR1 mutations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ariazi EA, Ariazi JL, Cordera F, Jordan VC (2006) Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem 6(3):181–202

    Article  CAS  PubMed  Google Scholar 

  2. Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, Kalyana-Sundaram S, Wang R, Ning Y, Hodges L et al (2013) Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet 45(12):1446–1451

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Lippman ME, Allegra JC (1980) Quantitative estrogen receptor analyses: the response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval. Cancer 46(12 Suppl):2829–2834

    Article  CAS  PubMed  Google Scholar 

  4. Speirs V, Parkes AT, Kerin MJ, Walton DS, Carleton PJ, Fox JN, Atkin SL (1999) Coexpression of estrogen receptor alpha and beta: poor prognostic factors in human breast cancer? Cancer Res 59(3):525–528

    CAS  PubMed  Google Scholar 

  5. Osborne CK, Schiff R (2003) Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast 12(6):362–367

    Article  PubMed  Google Scholar 

  6. Segal CV, Dowsett M (2014) Estrogen receptor mutations in breast cancer–new focus on an old target. Clin Cancer Res 20(7):1724–1726

    Article  CAS  PubMed  Google Scholar 

  7. Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA et al (2013) ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 45(12):1439–1445

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Wang P, Bahreini A, Gyanchandani R, Lucas PC, Hartmaier RJ, Watters RJ, Jonnalagadda AR, Trejo Bittar HE, Berg A, Hamilton RL et al (2016) Sensitive detection of mono- and polyclonal ESR1 mutations in primary tumors, metastatic lesions, and cell-free DNA of breast cancer patients. Clin Cancer Res 22(5):1130–1137

    Article  CAS  PubMed  Google Scholar 

  9. Schiavon G, Hrebien S, Garcia-Murillas I, Cutts RJ, Pearson A, Tarazona N, Fenwick K, Kozarewa I, Lopez-Knowles E, Ribas R et al (2015) Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med 7(313):313ra182

    Article  PubMed  PubMed Central  Google Scholar 

  10. Chandarlapaty S, Chen D, He W, Sung P, Samoila A, You D, Bhatt T, Patel P, Voi M, Gnant M et al (2016) Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial. JAMA Oncol. doi:10.1001/jamaoncol.2016.1279

    PubMed  Google Scholar 

  11. Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Inao T, Sueta A, Fujiwara S, Omoto Y, Iwase H (2016) Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients. Oncotarget. doi:10.18632/oncotarget.8839

    Google Scholar 

  12. Spoerke JM, Gendreau S, Walter K, Qiu J, Wilson TR, Savage H, Aimi J, Derynck MK, Chen M, Chan IT et al (2016) Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nat Commun 7:11579

    Article  PubMed  PubMed Central  Google Scholar 

  13. Glenn TC (2011) Field guide to next-generation DNA sequencers. Mol Ecol Resour 11(5):759–769

    Article  CAS  PubMed  Google Scholar 

  14. Nakauchi C, Kagara N, Shimazu K, Shimomura A, Naoi Y, Shimoda M, Kim SJ, Noguchi S (2016) Detection of TP53/PIK3CA mutations in cell-free plasma DNA from metastatic breast cancer patients using next generation sequencing. Clin Breast Cancer. doi:10.1016/j.clbc.2016.05.004

    PubMed  Google Scholar 

  15. Rothé F, Laes JF, Lambrechts D, Smeets D, Vincent D, Maetens M, Fumagalli D, Michiels S, Drisis S, Moerman C et al (2014) Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann Oncol 25(10):1959–1965

    Article  PubMed  Google Scholar 

  16. Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11(2):155–168

    CAS  PubMed  Google Scholar 

  17. Yamamoto N, Nakayama T, Kajita M, Miyake T, Iwamoto T, Kim SJ, Sakai A, Ishihara H, Tamaki Y, Noguchi S (2012) Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARβ2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay. Breast Cancer Res Treat 132(1):165–173

    Article  CAS  PubMed  Google Scholar 

  18. Morimoto K, Kim SJ, Tanei T, Shimazu K, Tanji Y, Taguchi T, Tamaki Y, Terada N, Noguchi S (2009) Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci 100(6):1062–1068

    Article  CAS  PubMed  Google Scholar 

  19. Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, Ferrer-Lozano J, Perez-Fidalgo JA, Cristofanilli M, Gómez H et al (2014) Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res 20(7):1757–1767

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Niu J, Andres G, Kramer K, Kundranda MN, Alvarez RH, Klimant E, Parikh AR, Tan B, Staren ED, Markman M (2015) Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients. Onco Targets Ther 8:3323–3328

    Article  PubMed  PubMed Central  Google Scholar 

  21. Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Inao T, Sueta A, Fujiwara S, Omoto Y, Iwase H (2015) Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens. Transl Res 166(6):540–553e.542

    Article  CAS  PubMed  Google Scholar 

  22. Fribbens C, O’Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, Cristofanilli M, Andre F, Loi S, Loibl S et al (2016) Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J Clin Oncol 34(25):2961–2968

    Article  PubMed  Google Scholar 

  23. Diaz LA, Bardelli A (2014) Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 32(6):579–586

    Article  PubMed  PubMed Central  Google Scholar 

  24. Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, Liu CL, Neal JW, Wakelee HA, Merritt RE et al (2014) An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 20(5):548–554

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B (2011) Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci USA 108(23):9530–9535

    Article  PubMed  PubMed Central  Google Scholar 

  26. Kukita Y, Matoba R, Uchida J, Hamakawa T, Doki Y, Imamura F, Kato K (2015) High-fidelity target sequencing of individual molecules identified using barcode sequences: de novo detection and absolute quantitation of mutations in plasma cell-free DNA from cancer patients. DNA Res 22(4):269–277

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Fuqua SA, Rechoum Y, Gu G (2016) ESR1 mutations in cell-free DNA of breast cancer: predictive “tip of the iceberg”. JAMA Oncol 2(10):1315–1316

    Article  PubMed  Google Scholar 

  28. Susa T, Ikaga R, Kajitani T, Iizuka M, Okinaga H, Tamamori-Adachi M, Okazaki T (2015) Wild-type and specific mutant androgen receptor mediates transcription via 17β-estradiol in sex hormone-sensitive cancer cells. J Cell Physiol 230(7):1594–1606

    Article  CAS  PubMed  Google Scholar 

  29. Gelsomino L, Gu G, Rechoum Y, Beyer AR, Pejerrey SM, Tsimelzon A, Wang T, Huffman K, Ludlow A, Andò S et al (2016) ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling. Breast Cancer Res Treat 157(2):253–265

    Article  CAS  PubMed  Google Scholar 

  30. Fuqua SA, Gu G, Rechoum Y (2014) Estrogen receptor (ER) α mutations in breast cancer: hidden in plain sight. Breast Cancer Res Treat 144(1):11–19

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Barone I, Cui Y, Herynk MH, Corona-Rodriguez A, Giordano C, Selever J, Beyer A, Andò S, Fuqua SA (2009) Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway. Cancer Res 69(11):4724–4732

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Barone I, Iacopetta D, Covington KR, Cui Y, Tsimelzon A, Beyer A, Andò S, Fuqua SA (2010) Phosphorylation of the mutant K303R estrogen receptor alpha at serine 305 affects aromatase inhibitor sensitivity. Oncogene 29(16):2404–2414

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Katsuhide Yoshidome (Osaka Police Hospital, Osaka, Japan) for kindly providing the tumor samples examined in this manuscript.

Author information

Authors and Affiliations

  1. Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, 2-2-E10 Yamadaoka, Suita-shi, Osaka, 565-0871, Japan

    Takehiro Yanagawa, Naofumi Kagara, Tomohiro Miyake, Tomonori Tanei, Yasuto Naoi, Masafumi Shimoda, Kenzo Shimazu, Seung Jin Kim & Shinzaburo Noguchi

Authors
  1. Takehiro Yanagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naofumi Kagara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tomohiro Miyake
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tomonori Tanei
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yasuto Naoi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masafumi Shimoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kenzo Shimazu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Seung Jin Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Shinzaburo Noguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Naofumi Kagara.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yanagawa, T., Kagara, N., Miyake, T. et al. Detection of ESR1 mutations in plasma and tumors from metastatic breast cancer patients using next-generation sequencing. Breast Cancer Res Treat 163, 231–240 (2017). https://doi.org/10.1007/s10549-017-4190-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-017-4190-z

Keywords

Search

Navigation